For the first time in 6 years, the American College of Rheumatology published new guidelines for the treatment of rheumatoid arthritis. With 1.3 million Americans currently diagnosed with Rheumatoid Arthritis, this specialty condition often finds itself being managed in multiple sites of care. Learn how pharmacy contributes to the team care of RA patients with this guideline update.

Upon successful completion of this application-based CPE course, pharmacy technicians should be able to:
1. List the signs and symptoms of rheumatoid arthritis
2. Identify commonly used medications for the treatment of rheumatoid arthritis
3. Determine eligible patients for disease activity scale assessment
4. Assess the medication profile of patients with rheumatoid arthritis for potential common adverse reactions of disease-modifying antirheumatic drugs (DMARDS)

Jonathan Ogurchak, PharmD, CSP
STACK, CEO  

Jonathan Ogurchak does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course.

Financial support was provided for this course through an unrestricted educational grant from Biologics by McKesson.

Course includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable
Initial Release Date: September 16, 2021
Planned Expiration Date: September 16, 2024

Copyright 2021, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

RV3-4.24/EXP